YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

Aggressive Non-hodgkin's Lymphoma Treated at the Institute of Oncology, Istanbul - Treatment, Outcome, and Prognostic Factors

dc.authorid Eralp, Yesim/0000-0001-9603-4755
dc.authorscopusid 6701753460
dc.authorscopusid 8712720400
dc.authorscopusid 6602597500
dc.authorscopusid 7005732398
dc.authorscopusid 6603910613
dc.authorscopusid 6701530171
dc.authorwosid Basaran, Mert/Aat-7762-2020
dc.authorwosid Eralp, Yesim/Aad-7194-2020
dc.contributor.author Alici, S
dc.contributor.author Bavbek, SE
dc.contributor.author Kaytan, E
dc.contributor.author Basaran, M
dc.contributor.author Eralp, Y
dc.contributor.author Onat, H
dc.date.accessioned 2025-05-10T17:15:09Z
dc.date.available 2025-05-10T17:15:09Z
dc.date.issued 2002
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp Istanbul Univ, Inst Oncol, Istanbul, Turkey en_US
dc.description Eralp, Yesim/0000-0001-9603-4755 en_US
dc.description.abstract In an unselected group of patients with aggressive non-Hodgkin's lymphoma (A-NHL) treated at our institution during a 10-year period (1989-1998), we studied the treatment outcome and influence of possible prognostic factors. Two hundred one patients with A-NHL were analyzed retrospectively with regard to personal, treatment, and disease-specific characteristics. Median age was 55 years (range: 16-87 years) and the male:female ratio was 1.5. During a median follow-up of 26 months, the overall response rate was 74% (complete response 63%, partial response 11%). The 2- and 5-year disease-free survival rates were 49 +/- 3% (mean +/- SEM) and 41 +/- 4%, respectively. In a univariate analysis, the following variables were associated with prognosis in terms of survival: patient age, clinical stage, performance status, B symptoms, erythrocyte sedimentation rate, treatment response, and histologic grade of tumor. In multivariate analyses, patient age, performance status, and treatment response emerged as independent prognostic factors for survival. en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.doi 10.1097/00000421-200210000-00016
dc.identifier.endpage 508 en_US
dc.identifier.issn 0277-3732
dc.identifier.issn 1537-453X
dc.identifier.issue 5 en_US
dc.identifier.pmid 12393993
dc.identifier.scopus 2-s2.0-0036793760
dc.identifier.scopusquality Q3
dc.identifier.startpage 502 en_US
dc.identifier.uri https://doi.org/10.1097/00000421-200210000-00016
dc.identifier.uri https://hdl.handle.net/20.500.14720/8537
dc.identifier.volume 25 en_US
dc.identifier.wos WOS:000178546900016
dc.identifier.wosquality Q3
dc.language.iso en en_US
dc.publisher Lippincott Williams & Wilkins en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Non-Hodgkin'S Lymphoma en_US
dc.subject Treatment en_US
dc.subject Prognostic Factors en_US
dc.title Aggressive Non-hodgkin's Lymphoma Treated at the Institute of Oncology, Istanbul - Treatment, Outcome, and Prognostic Factors en_US
dc.type Article en_US

Files